On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- Govt to Provide Vaccines for All Workplace Programs Requested
July 5, 2021
- MHLW Urges Wholesalers to Strictly Enforce Legal Compliance after Bid-Rigging Ruling
July 2, 2021
- Sakigake Tag Revoked for Eisai’s E7090 after Pemazyre Approval
July 1, 2021
- Vaccines for All People to Be Delivered to Local Govts by October-End: Kono
June 30, 2021
- MHLW to Start Study on US, European Schemes on ADR Evaluation
June 29, 2021
- MHLW Extends Maximum Biz Suspension Period to 180 Days in All Prefectures
June 29, 2021
- Japan Issues Guidelines on Drug Delivery by Drones; Operation Plan, Quality Assurance Required
June 28, 2021
- Japan Allots 33 Million Moderna Shots to Companies, 17 Million to Local Govts: Minister
June 28, 2021
- PMDA Reviewing New Safety Risk for Evenity, 13 Other APIs
June 28, 2021
- MHLW Announces Recommendation for Cannabis Drug Debate
June 28, 2021
- Japan Approves Verquvo, Evrysdi, 2 CGRP Migraine Meds and More
June 24, 2021
- Japan to Stop Accepting Requests for Moderna Vaccines for Workplace Inoculations
June 24, 2021
- Panel OKs PI Study for Temcell Use in Refractory Skin Ulcer
June 24, 2021
- PMDA COVID-19 Vaccine Consultation Draws 129 Inquiries in 8 Months
June 24, 2021
- Chuikyo OKs Drug Price Survey Plan for FY2022 Revision
June 24, 2021
- Drug Pricing Rules to Be Applied to Oncolytic Virus Delytact: Chuikyo
June 24, 2021
- MHLW Panel Roughly OKs Scheme for Generic Makers to Join Revlimid Risk Management Program
June 23, 2021
- Orphan Status Granted to Unitalc, TransCon PTH
June 23, 2021
- Japan OKs 2021 Fiscal Policy Blueprint, Vows Transparency in Drug Pricing
June 21, 2021
- MHLW to Prioritize Application Reviews for COVID-19 Products, Expecting Rush of Filings
June 21, 2021
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…